Drug Type Small molecule drug |
Synonyms 4-Methylumbelliferone, 4-methylumbelliferone |
Target |
Action antagonists, inhibitors |
Mechanism HMMR antagonists(hyaluronan mediated motility receptor antagonists), Hyaluronic acid inhibitors(Hyaluronic acid inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date (13 May 2025), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Biliary Tract Diseases | - | - | 13 May 2025 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myocardial Ischemia | Preclinical | Iran | 06 Jan 2024 | |
Reperfusion Injury | Preclinical | Iran | 06 Jan 2024 | |
Hepatocellular Carcinoma | Preclinical | Italy | 20 Apr 2023 | |
Brain Diseases | Preclinical | France | 16 Nov 2022 |